Related Experiment Video

Updated: Feb 14, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

11.9K

miR-139-5p inhibits isoproterenol-induced cardiac hypertrophy by targetting c-Jun

Su Ming1,2, Wang Shui-Yun3, Qiu Wei4

  • 1Department of Clinical Laboratory, Peking University People's Hospital, Beijing, People's Republic of China suming28@163.com jzwang@hotmail.com.

Bioscience Reports
|February 15, 2018
PubMed

Insights

MicroRNA-139-5p (miR-139-5p) is down-regulated in hypertrophic cardiomyopathy (HCM). Lower miR-139-5p levels promote cardiac hypertrophy by increasing c-Jun expression, suggesting miR-139-5p is a protective factor.

Area of Science:

  • Cardiovascular Biology
  • Molecular Genetics
  • Biochemistry

Background:

  • Hypertrophic cardiomyopathy (HCM) is a genetic heart condition causing cardiac hypertrophy and heart failure.
  • Previous studies identified reduced miR-139-5p levels in HCM patients, but its specific role was unknown.

Purpose of the Study:

  • To investigate the regulatory role of miR-139-5p in cardiac hypertrophy.
  • To elucidate the molecular mechanism by which miR-139-5p influences cardiac hypertrophy.

Main Methods:

  • Analysis of miR-139-5p expression in human and mouse cardiac tissues.
  • In vitro studies using neonatal rat cardiomyocytes (NRCMs) involving miR-139-5p knockdown and overexpression.
  • Investigation of the interaction between miR-139-5p and c-Jun.

Main Results:

  • miR-139-5p expression was significantly down-regulated in HCM patient hearts and in mice after transverse aortic constriction (TAC).
  • miR-139-5p knockdown in NRCMs induced cardiomyocyte enlargement and increased atrial natriuretic polypeptide (ANP) expression.
  • Overexpression of miR-139-5p inhibited isoproterenol (ISO)-induced cardiomyocyte hypertrophy and ANP/brain natriuretic peptide (BNP) expression.
  • miR-139-5p directly targets and inhibits c-Jun expression, and c-Jun knockdown attenuated hypertrophy caused by miR-139-5p deficiency.

Conclusions:

  • miR-139-5p is downregulated in the hearts of HCM patients.
  • miR-139-5p inhibits cardiac hypertrophy, at least partly, by targeting c-Jun.
  • miR-139-5p acts as a protective microRNA against cardiac hypertrophy.

Keywords:
c-Junhypertrophic cardiomyopathyisoproterenolmiR-139-5p

More Related Videos

O-Ring Aortic Banding Versus Traditional Transverse Aortic Constriction for Modeling Pressure Overload-Induced Cardiac Hypertrophy09:24

O-Ring Aortic Banding Versus Traditional Transverse Aortic Constriction for Modeling Pressure Overload-Induced Cardiac Hypertrophy

Published on: October 6, 2022

4.3K
Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model10:18

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model

Published on: June 29, 2014

17.6K

Related Concept Videos

Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.4K
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
92.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K
Cardiac Output II: Effect of Stroke Volume on Cardiac Output01:22

Cardiac Output II: Effect of Stroke Volume on Cardiac Output

Cardiac output (CO), the amount of blood the heart pumps per minute, is a parameter in cardiovascular physiology determined by stroke volume and heart rate. Stroke volume, the amount of blood pushed from one of the ventricles per heartbeat, is influenced by preload, afterload, and contractility.
Preload
Preload refers to the initial elongation of the cardiac myocytes before contraction and is related to the volume of blood filling the heart at the end of diastole, or end-diastolic volume. The...
3.6K
Cardiac Output I:Effect of Heart Rate on Cardiac Output01:19

Cardiac Output I:Effect of Heart Rate on Cardiac Output

Cardiac Output
Cardiac output (CO) refers to the total amount of blood ejected by one of the ventricles in liters per minute (L/min). In a resting adult, CO ranges from 5 to 6 L/min, adjusting according to the body's metabolic requirements.
Effect of Heart Rate on Cardiac Output
Cardiac output adapts to metabolic demands during stress, physical activity, or illness. The autonomic nervous system regulates heart rate via the sinoatrial node. The parasympathetic nervous system decreases heart...
2.8K
The Cardiac Cycle01:13

The Cardiac Cycle

The heart beats rhythmically in a sequence called the cardiac cycle—a rapid coordination of contraction (systole) and relaxation (diastole).
The Process
Electrical signals—sent from the sinoatrial (SA) node in the right atrial wall to the atrioventricular (AV) node between the right atrium and right ventricle—cause both atria to simultaneously contract. When the signal reaches the AV node, it pauses for approximately a tenth of a second, allowing the atria to contract and...
99.1K